Chemical Property of Chlorzoxazone
Chemical Property:
- Appearance/Colour:White to off-white solid
- Melting Point:191-192 °C
- Refractive Index:1.5557 (estimate)
- Boiling Point:336.9 °C at 760 mmHg
- PKA:pKa 8.3 (Uncertain)
- Flash Point:157.5 °C
- PSA：46.26000
- Density:1.486 g/cm3
- LogP:2.18680
- Storage Temp.:-20°C Freezer
- Solubility.:DMSO: soluble50mg/mL, clear
- Water Solubility.:0.1 g/100 mL
- XLogP3:1.8
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:2
- Rotatable Bond Count:0
- Exact Mass:168.9930561
- Heavy Atom Count:11
- Complexity:185
- Purity/Quality:
-
98.5%min *data from raw suppliers
Chlorzoxazone, substrate for Cytochrome P450 2E *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn, 
T, 
Xi
- Hazard Codes:Xn,T,Xi
- Statements:
22-36/37/38-20/21/22
- Safety Statements:
26-36-24/25-37/39
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Drug Classes:Autonomic Agents: Muscle Relaxants, Central
- Canonical SMILES:C1=CC2=C(C=C1Cl)NC(=O)O2
- Recent ClinicalTrials:Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently
- Recent EU Clinical Trials:An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam, chlorzoxazone, caffeine)
-
Indications
Chlorzoxazone is suitable for the treatment of various kinds of acute and chronic soft tissue (muscles, ligaments and fascia) sprain, contusion, muscle pain after exercise, pain caused by muscle strain and the muscle spasms caused by the central nervous system lesions as well as chronic fasciitis.
-
Uses
It can be used as pharmaceutical intermediates.
It can be used as central muscle relaxants, for being applied to a variety of soft tissue pain caused by chronic sprain, contusion and muscle strain as well as muscle spasms and pain caused by the central nervous system and so on. Chlorzoxazone is a benzoxazolone derivative that causes skeletal muscle relaxation and blocks spasticity in clinical studies. Chlorzoxazone enhances small and intermediate conductance calcium-activated potassium channels (EC50s = 87 and 98 μM for KCa2.2 and KCa3.1, respectively). The cytochrome P450 isoform CYP2E1 converts chlorzoxazone to 6-hydroxy chlorzoxazone . The urinary excretion of this 6-hydroxy metabolite is often used as a probe of CYP2E1 activity in studies of hepatotoxicity. For the relief of discomfort associated with acute painful musculoskeletal conditions.
-
Description
Chlorzoxazone is a muscle relaxant. It acts by blocking nerve
impulses or pain sensations that are sent to brain. Typically, it
is used together with rest and physical therapy to treat skeletal
muscle conditions such as pain or injury. Chlorzoxazone,
5-chloro-2-benzoxazolione, is synthesized by a heterocyclization
reaction of 2-amino-4-chlorophenol with phosgene.
Skeletal muscle relaxants have conventionally been classified
into one group; however, they are actually a heterogeneous
group of medications commonly used to treat two different
types of underlying conditions – spasticity from upper motor
neuron syndromes and muscular pain or spasms from
peripheral musculoskeletal conditions. Medications classified
as skeletal muscle relaxants are baclofen, carisoprodol,
chlorzoxazone, cyclobenzaprine, dantrolene, metaxalone,
methocarbamol, orphenadrine, and tizanidine. These drugs
may impair mental and/or physical abilities required for
driving vehicles. As a class, skeletal muscle relaxants have
central nervous system (CNS)-related side effects: drowsiness,
dizziness, decreased alertness, blurred vision, and ataxia.
Their use has been associated with a twofold increase in the
risk for motor vehicle crashes. Muscle relaxants are included
in the ‘Beers List’ of potentially inappropriate medications
in older adults. Most muscle relaxants are poorly tolerated by
elderly patients because they cause anticholinergic adverse
effects, sedation, and weakness. Although extremely uncommon,
Chlorzoxazone may yield to idiosyncratic and
unpredictable type of liver toxicity. The concomitant use of
alcohol or other CNS depressants may have an additive effect.
Individuals on chlorzoxazone containing drugs should be
monitored for abnormal liver enzymes (e.g., aspartate transaminase
(AST), alanine transaminase (ALT), alkaline phosphatase,
bilirubin, etc.). Chlorzoxazone is a centrally acting muscle relaxant and activator of small and intermediate conductance calcium-activated potassium channels (EC50s = 87 and 98 μM for KCa2.2 and KCa3.1, respectively). In vivo, chlorzoxazone (10 mg/kg) decreases alcohol but not water intake in a dose-dependent manner and reduces the propensity for rapid initial alcohol intake in rats with intermittent, but not continuous, access to alcohol. Formulations containing chlorzoxazone have been used in the treatment of pain and stiffness caused by muscle spasm. This product is also available as an analytical reference standard . Chlorzoxazone (Item No. 25826) is an analytical reference standard categorized as a skeletal muscle relaxant. This product is intended for analytical forensic applications. This product is also available as a general research tool .
